The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Rick Doblin, Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Rick Doblin

Abstract

Case reports indicate that psychiatrists administered ±3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recreational use of MDMA as 'Ecstasy' resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder, refractory to both psychotherapy and psychopharmacology, were randomly assigned to psychotherapy with concomitant active drug (n = 12) or inactive placebo (n = 8) administered during two 8-h experimental psychotherapy sessions. Both groups received preparatory and follow-up non-drug psychotherapy. The primary outcome measure was the Clinician-Administered PTSD Scale, administered at baseline, 4 days after each experimental session, and 2 months after the second session. Neurocognitive testing, blood pressure, and temperature monitoring were performed. After 2-month follow-up, placebo subjects were offered the option to re-enroll in the experimental procedure with open-label MDMA. Decrease in Clinician-Administered PTSD Scale scores from baseline was significantly greater for the group that received MDMA than for the placebo group at all three time points after baseline. The rate of clinical response was 10/12 (83%) in the active treatment group versus 2/8 (25%) in the placebo group. There were no drug-related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases. MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.

Trial registration: ClinicalTrials.gov NCT00090064.

Figures

Figure 1.
Figure 1.
Flow Diagram.
Figure 2.
Figure 2.
Study Visits.
Figure 3.
Figure 3.
CAPS Mean Scores by Group for Time 1-Time 4.
Figure 4.
Figure 4.
IES-R Mean Scores by Group for Time 1-Time 4.

References

    1. Baggott MJ, Galloway G, Jang M, Didier R, Pournajafi-Nazarloo H, Carter CS, et al. (2008) 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and prazosin interactions in humans. 70th Annual Meeting of the College on Problems of Drug Dependence. San Juan, Puerto Rico.
    1. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58: 639–650
    1. Benish SG, Imel ZE, Wampold BE. (2008) The relative efficacy of bona fide psychotherapies for treating post-traumatic stress disorder: a meta-analysis of direct comparisons. Clin Psychol Rev 28: 746–758
    1. Benzenhoefer UP, Passie T. (2006) The early history of ecstasy. Nervenartz 77: 95–96 (98–99
    1. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283: 1837–1844
    1. Breslau N. (2001) The epidemiology of posttraumatic stress disorder: what is the extent of the problem? J Clin Psychiatry 62: 16–22
    1. Breslau N, Davis GC. (1992) Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity. Am J Psychiatry 149: 671–675
    1. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455–466
    1. Cloitre M. (2009) Effective psychotherapies for posttraumatic stress disorder: a review and critique. CNS Spectr 14: 32–43
    1. Cohen BE, Marmar C, Ren L, Bertenthal D, Seal KH. (2009) Association of cardiovascular risk factors with mental health diagnoses in Iraq and Afghanistan war veterans using VA health care. JAMA 302: 489–492
    1. Committee on Treatment of Posttraumatic Stress Disorder, Institute of Medicine (2008) Posttraumatic stress disorder: an assessment of the evidence. Washington, DC: The National Academies Press
    1. Davis M, Barad M, Otto M, Southwick S. (2006) Combining pharmacotherapy with cognitive behavioral therapy: traditional and new approaches. J Trauma Stress 19: 571–581
    1. de Jong JT, Komproe IH, Van Ommeren M. (2003) Common mental disorders in post-conflict settings. Lancet 36: 2128–2130
    1. Derogatis LR. (1994) SCL-90-R: Administration, Scoring and Procedures Manual. Minneapolis: National Computer Systems, Inc
    1. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. (2007) Oxytocin improves “mind-reading” in humans. Biol Psychiatry 61: 731–733
    1. Dumont GJ, Sweep FC, van der, Steen R, Hermsen R, Donders AR, Touw DJ, et al. (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4: 359–366
    1. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O’Mathuna B, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323: 954–962
    1. First MB, Gibbon M, Spitzer RL, Williams J, Benjamin L. (1997) Structured clinical interview for Axis II DSM-IV disorders: Patient Edition (SCID II). Washington, DC: American Psychiatric Press, Inc
    1. First MB, Spitzer RL, Gibbon M, Williams J. (1994) Structured clinical interview for Axis I DSM -IV disorders: Patient Edition (SCID-I/P). New York: NYSPI
    1. Foa EB, Hembree EA, Rothbaum BO. (2007) Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences: therapist guide. New York, NY: Oxford University Press
    1. Foa EB, Keane TM, Friedman MJ, Cohen JA. (2009) Effective treatments for PTSD, practice guidelines from the international society for traumatic stress studies, 2nd edn New York, NY: Guilford Press
    1. Foa EB, Kozak MJ. (1986) Emotional Processing of Fear: Exposure and corrective information. Psychol Bull 99: 20–35
    1. Frayne SM, Seaver MR, Loveland S, Christiansen CL, Spiro A, Parker VA. (2004) Burden of medical illness in women with depression and posttraumatic stress disorder. Arch Intern Med 164: 1306–1312
    1. Freudenmann RW, Oxler F, Bernschneider-Reif S. (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 101: 1241–1245
    1. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. (2000) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388–395
    1. Greer GR, Tolbert R. (1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30: 371–379
    1. Grob CS, Poland RE, Chang L, Ernst T. (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73: 103–107
    1. Grof S. (2000) Psychology of the Future. Albany, NY: State University of New York Press
    1. Gronwall DM. (1977) Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 44: 367–373
    1. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162: 396–405
    1. Hembree EA, Foa EB, Dorfan NM, Street GP, Kowalski J, Tu X. (2003) Do patients drop out prematurely from exposure therapy for PTSD?. J Trauma Stress 16: 555–562
    1. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. (2004) Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 351: 13–22
    1. Ipser J, Seedat S, Stein DJ. (2006) Pharmacotherapy for post-traumatic stress disorder – a systematic review and meta-analysis. S Afr Med J 96: 1088–1096
    1. Jaycox LF, Foa EB. (1999) Obstacles in implementing exposure therapy for PTSD: Case discussions and practical solutions. Clin Psychol Psychother 3: 176–184
    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627
    1. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25: 11489–11493
    1. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30: 320–332
    1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. (2005) Oxytocin increases trust in humans. Nature 435: 673–676
    1. Liechti ME, Baumann C, Gamma A, Vollenweider FX. (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513–521
    1. Liechti ME, Gamma A, Vollenweider FX. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161–168
    1. Liechti ME, Vollenweider FX. (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol 14: 269–274
    1. Marshall RD, Beebe KL, Oldham M, Zaninelli R. (2001) Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 145: 1982–1988
    1. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136–145
    1. Metzner R, Adamson S. (2001) Using MDMA in healing, psychotherapy and spiritual practice. Ecstasy: the complete guide. Rochester, VT: Inner Traditions; 182–207
    1. Mirushina MN, Boone KB, D’Elia LF. (1999) Handbook of normative data for neuropsychological assessment. New York, NY: Oxford University Press
    1. Ogden PKM, Pain C. (2006) Trauma and the body. New York, NY: W.W. Norton & Company
    1. Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. (1971) The experimental use of psychedelic (LSD) psychotherapy. Int J Clin Pharmacol 4: 446–454
    1. Passie T, Hartmann U, Schneider U, Emrich HM, Kruger TH. (2005) Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. Med Hypotheses 64: 899–903
    1. Perkonigg A, Kessler RC, Storz S, Wittchen HU. (2000) Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity. Acta Psychiatr Scand 101: 46–59
    1. Randolph C, Tierney MC, Mohr E, Chase TN. (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20: 310–319
    1. Rauch SL, Shin LM, Phelps EA. (2006) Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research – past, present, and future. Biol Psychiatry 60: 376–382
    1. Rothbaum BO, Cahill SP, Foa EB, Davidson J, Compton J, Connor KM, et al. (2006) Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 19: 625–638
    1. Sargent W, Slater E, Kelly D. (1972) An Introduction to Physical Methods of Treatment in Psychiatry. Edinburgh and London: Churchill Livingstone
    1. Siegel D. (1999) The developing mind. New York, NY: Guilford Press
    1. Stein DJ, Ipser J, McAnda N. (2009) Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 14: 25–31
    1. Tancer ME, Johanson CE. (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65: 97–101
    1. Tancer M, Johanson CE. (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189: 565–573
    1. Tanielian TL, Jaycox L. the Rand Corporation (2008) Invisible wounds of war: psychological and cognitive injuries, their consequences, and services to assist recovery. Santa Monica, CA: RAND
    1. Thabet AA, Vostanis P. (1999) Post-traumatic stress reactions in children of war. J Child Psychol Psychiatry 40: 385–391
    1. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007) A role for oxytocin and 5-HT (1A) receptors in the prosocial effects of 3,4-methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146: 509–514
    1. Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B, et al. (2004) Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 161: 3–31
    1. Vollenweider FX, Gamma A, Liechti M, Huber T. (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241–251
    1. Weathers FW, Keane TM, Davidson JR. (2001) Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13: 132–156
    1. Weine SM, Becker DF, McGlashan TH, Laub D, Lazrove S, Vojvoda D, et al. (1995) Psychiatric consequences of “ethnic cleansing”: clinical assessments and trauma testimonies of newly resettled Bosnian refugees. Am J Psychiatry 152: 536–542
    1. Weiss DM. (1997) The Impact of Event Scale-Revised. In: Wilson JP, Keanne TM. (eds) Assessing Psychological Trauma and PTSD. New York: Guilford Press
    1. Wilbarger P, Wilbarger J. (1997) Sensory defensiveness and related social/emotional and neurological problems. Van Nuys, CA: Wilbarger
    1. Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, et al. (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20: 400–410
    1. Zak PJ, Kurzban R, Matzner WT. (2005) Oxytocin is associated with human trustworthiness. Horm Behav 48: 522–527

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe